Definitive Healthcare (NASDAQ:DH – Get Free Report) had its price target lowered by analysts at Deutsche Bank Aktiengesellschaft from $7.00 to $5.00 in a report issued on Friday, Benzinga reports. The brokerage currently has a “hold” rating on the stock. Deutsche Bank Aktiengesellschaft’s price target would suggest a potential upside of 26.26% from the company’s current price.
A number of other equities research analysts have also recently issued reports on the stock. JPMorgan Chase & Co. cut shares of Definitive Healthcare from a “neutral” rating to an “underweight” rating and dropped their target price for the stock from $7.00 to $5.00 in a research report on Wednesday, July 31st. Morgan Stanley dropped their target price on shares of Definitive Healthcare from $9.00 to $5.00 and set an “equal weight” rating for the company in a research report on Tuesday. Needham & Company LLC reiterated a “hold” rating on shares of Definitive Healthcare in a research report on Tuesday. Canaccord Genuity Group dropped their target price on shares of Definitive Healthcare from $10.00 to $8.00 and set a “hold” rating for the company in a research report on Wednesday, May 8th. Finally, Robert W. Baird dropped their target price on shares of Definitive Healthcare from $6.00 to $5.00 and set a “neutral” rating for the company in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and two have given a buy rating to the stock. According to MarketBeat, Definitive Healthcare has an average rating of “Hold” and an average target price of $7.55.
View Our Latest Research Report on Definitive Healthcare
Definitive Healthcare Price Performance
Definitive Healthcare (NASDAQ:DH – Get Free Report) last announced its earnings results on Monday, August 5th. The company reported $0.09 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.09. The business had revenue of $63.70 million during the quarter, compared to analysts’ expectations of $63.19 million. Definitive Healthcare had a negative net margin of 78.16% and a positive return on equity of 0.51%. The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same quarter last year, the company posted $0.08 EPS. Equities research analysts expect that Definitive Healthcare will post 0.09 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Definitive Healthcare
Several institutional investors have recently modified their holdings of DH. Tower Research Capital LLC TRC grew its position in shares of Definitive Healthcare by 599.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,786 shares of the company’s stock worth $58,000 after buying an additional 4,959 shares during the period. Norden Group LLC acquired a new stake in shares of Definitive Healthcare during the 1st quarter worth approximately $83,000. Berry Wealth Group LP acquired a new stake in shares of Definitive Healthcare during the 1st quarter worth approximately $99,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Definitive Healthcare by 31.4% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 21,292 shares of the company’s stock worth $116,000 after buying an additional 5,083 shares during the period. Finally, Susquehanna Fundamental Investments LLC acquired a new stake in shares of Definitive Healthcare during the 1st quarter worth approximately $120,000. Institutional investors and hedge funds own 98.67% of the company’s stock.
About Definitive Healthcare
Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.
Recommended Stories
- Five stocks we like better than Definitive Healthcare
- Profitably Trade Stocks at 52-Week Highs
- The Cannabis Sector: Profitability Takes Center Stage
- Which Wall Street Analysts are the Most Accurate?
- Amazon’s Stock Plunge: Is a Prime Buying Opportunity Knocking?
- How to Use Stock Screeners to Find Stocks
- Buy the Dip in e.l.f. Beauty: Analysts Point to a New High
Receive News & Ratings for Definitive Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Definitive Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.